The decisions are part of the company's restructuring efforts after it was unable to extend deferral of its debt payment with its senior lender.
The moves are part of an effort to consolidate and reduce costs related to administrative, finance, and operational support functions.
The firm said that it planned to lay off its oncology sales team in order to focus on women's health, despite launching an oncology business unit last spring.
In October, Roche reported the tissue diagnostics business contributed 8 percent to diagnostics sales in the first nine months of 2016.
The firm's CEO Ramji Srinivasan said the layoffs would help focus the company on developing relationships with clinicians and medical providers.
In November, the company said it was selling off its biomedical commercialization and marketing services business in order to focus on its diagnostic offerings.
The company has scaled back its headcount from a peak of 115 employees to about 100 staff members, primarily on the commercial side.
Johnson & Johnson announced that it would be cutting about 3,000 jobs from its medical devices section.
The company said it earned approximately $128 million in revenue in 2015, and accessioned 42,000 total commercial diagnostic test samples.
Dragged down by sinking sales and test volumes at IDL, GeneNews looks to restructure its business.
Bioethicists disagree with a research team's decision to allow the return of risk results for adult-onset conditions from a newborn sequencing project, according to Reuters.
Alterations to particular gene may enable the Quechua of Peru to better tolerate high-altitude life, Ars Technica reports.
Nature News reports that additional South Korean researchers have included the names of children on scientific papers when they did not contribute to the work.
In PLOS this week: statistical approach to prioritize rare variant searches, gene expression alterations in chronic obstructive pulmonary disease, and more.